Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study

Pierre Soubeyran, Carine Bellera, Jean Goyard, Damien Heitz, Hervé Curé, Hubert Rousselot, Gilles Albrand, Véronique Servent, Olivier Saint Jean, Isabelle van Praagh, Jean-Emmanuel Kurtz, Stéphane Périn, Jean-Luc Verhaeghe, Catherine Terret, Christophe Desauw, Véronique Girre, Cécile Mertens, Simone Mathoulin-Pélissier, Muriel Rainfray, Pierre Soubeyran, Carine Bellera, Jean Goyard, Damien Heitz, Hervé Curé, Hubert Rousselot, Gilles Albrand, Véronique Servent, Olivier Saint Jean, Isabelle van Praagh, Jean-Emmanuel Kurtz, Stéphane Périn, Jean-Luc Verhaeghe, Catherine Terret, Christophe Desauw, Véronique Girre, Cécile Mertens, Simone Mathoulin-Pélissier, Muriel Rainfray

Abstract

Background: Geriatric Assessment is an appropriate method for identifying older cancer patients at risk of life-threatening events during therapy. Yet, it is underused in practice, mainly because it is time- and resource-consuming. This study aims to identify the best screening tool to identify older cancer patients requiring geriatric assessment by comparing the performance of two short assessment tools the G8 and the Vulnerable Elders Survey (VES-13).

Patients and methods: The diagnostic accuracy of the G8 and the (VES-13) were evaluated in a prospective cohort study of 1674 cancer patients accrued before treatment in 23 health care facilities. 1435 were eligible and evaluable. Outcome measures were multidimensional geriatric assessment (MGA), sensitivity (primary), specificity, negative and positive predictive values and likelihood ratios of the G8 and VES-13, and predictive factors of 1-year survival rate.

Results: Patient median age was 78.2 years (70-98) with a majority of females (69.8%), various types of cancer including 53.9% breast, and 75.8% Performance Status 0-1. Impaired MGA, G8, and VES-13 were 80.2%, 68.4%, and 60.2%, respectively. Mean time to complete G8 or VES-13 was about five minutes. Reproducibility of the two questionnaires was good. G8 appeared more sensitive (76.5% versus 68.7%, P = 0.0046) whereas VES-13 was more specific (74.3% versus 64.4%, P<0.0001). Abnormal G8 score (HR = 2.72), advanced stage (HR = 3.30), male sex (HR = 2.69) and poor Performance Status (HR = 3.28) were independent prognostic factors of 1-year survival.

Conclusion: With good sensitivity and independent prognostic value on 1-year survival, the G8 questionnaire is currently one of the best screening tools available to identify older cancer patients requiring geriatric assessment, and we believe it should be implemented broadly in daily practice. Continuous research efforts should be pursued to refine the selection process of older cancer patients before potentially life-threatening therapy.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. STARD flow diagram for patient…
Figure 1. STARD flow diagram for patient enrollments and exclusions in the ONCODAGE G8 study.
Footnote: *In total, ten G8 were incomplete, but six ‘abnormal’ scores were able to be imputed from the incomplete assessments.
Figure 2. ROC curve for G8 test…
Figure 2. ROC curve for G8 test v MGA reference standard in the ONCODAGE study*.
Footnote: * For each point on the curve the G8 threshold (above line) and the sensitivity and specificity (below line) are indicated, e.g. score of 14, sensitivity: 76.4%, specificity: 64.4%. Abbreviations: ROC =  Receiver Operating Characteristics; MGA =  Multidimensional Geriatric Assessment.

References

    1. Mitka M (2003) Too few older patients in cancer trials: experts say disparity affects research results and care. JAMA 290:27–28.
    1. Dale W, Mohile SG, Eldadah BA, Trimble EL, Schilsky RL, et al. (2012) Biological, Clinical, and Psychosocial Correlates at the Interface of Cancer and Aging Research. J Natl Cancer Inst 104:581–589.
    1. Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, et al. (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073–1081.
    1. Soubeyran P, Fonck M, Blanc-Bisson C, Blanc JF, Ceccaldi J, et al. (2012) Predictors of early death risk in older patients treated by first-line chemotherapy for cancer. J Clin Oncol 30:1829–1834.
    1. Hoppe S, Rainfray M, Fonck M, Hoppenreys L, Blanc JF, et al. (2013) Functional Decline in Older Patients With Cancer Receiving First-Line Chemotherapy. Journal of Clinical Oncology 31:3877–3882.
    1. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, et al. (2012) Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 118:3377–3386.
    1. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, et al. (2011) Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study. J Clin Oncol 29:3457–3465.
    1. Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, et al. (2005) Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 23:6865–6872.
    1. Aaldriks AA, Maartense E, le Cessie S, Giltay EJ, Verlaan HA, et al. (2011) Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy. Crit Rev Oncol Hematol 79:205–212.
    1. Kanesvaran R, Li H, Koo KN, Poon D (2011) Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer. J Clin Oncol 29:3620–3627.
    1. Caillet P, Canoui-Poitrine F, Vouriot J, Berle M, Reinald N, et al. (2011) Comprehensive Geriatric Assessment in the Decision-Making Process in Elderly Patients With Cancer: ELCAPA Study. J Clin Oncol 29:3636–3642.
    1. Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, et al. (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55:241–252.
    1. Extermann M, Aapro M, Audisio R, Balducci L, Droz JP, et al.. (2011) SIOG 10 priorities.
    1. McNeil C (2013) Geriatric oncology clinics on the rise. J Natl Cancer Inst 105:585–586.
    1. Gosney MA (2005) Clinical assessment of elderly people with cancer. Lancet Oncol 6:790–797.
    1. Rodin MB, Mohile SG (2007) A practical approach to geriatric assessment in oncology. J Clin Oncol 25:1936–1944.
    1. Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824–1831.
    1. Bellera CA, Rainfray M, Mathoulin-Pelissier S, Mertens C, Delva F, et al. (2012) Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 23:2166–2172.
    1. Mathoulin-Pélissier S, Bellera CA, Rainfray M, Soubeyran P (2013) Screening methods for geriatric frailty. Lancet Oncol 14:e1–e2.
    1. Wedding U, Rohrig B, Klippstein A, Pientka L, Hoffken K (2007) Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol 133:945–950.
    1. Cigolle CT, Langa KM, Kabeto MU, Tian Z, Blaum CS (2007) Geriatric conditions and disability: the Health and Retirement Study. Ann Intern Med 147:156–164.
    1. Cohen J (1960) A coefficient of agreement for nominal scales. Education and Psychological Measurements 20:37–46.
    1. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, et al. (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med 138:40–44.
    1. Biganzoli L, Boni L, Becheri D, Zafarana E, Biagioni C, et al. (2013) Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening tool? Ann Oncol 24:494–500.
    1. Extermann M, Green T, Tiffenberg G, Rich C (2009) Validation of the Senior Adult Oncology Program (SAOP) 2 screening questionnaire. Crit Rev Oncol Hematol 69:183–185.
    1. Kellen E, Bulens P, Deckx L, Schouten H, Van Dijk M, et al. (2010) Identifying an accurate pre-screening tool in geriatric oncology. Crit Rev Oncol Hematol 75:243–248.
    1. Luce S, de Breucker S, van Gossum Au, Demols A, Mekinda Z, et al. (2012) How to identify older patients with cancer who should benefit from comprehensive geriatric assessment? J Ger Oncol 3:351–358.
    1. Luciani A, Ascione G, Bertuzzi C, Marussi D, Codeca C, et al. (2010) Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol 28:2046–2050.
    1. Luciani A, Dottorini L, Battisti N, Bertuzzi C, Caldiera S, et al. (2013) Screening elderly cancer patients for disabilities: evaluation of study of osteoporotic fractures (SOF) index and comprehensive geriatric assessment (CGA). Ann Oncol 24:469–474.
    1. Mohile SG, Bylow K, Dale W, Dignam J, Martin K, et al. (2007) A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 109:802–810.
    1. Molina-Garrido MJ, Guillen-Ponce C (2011) Comparison of two frailty screening tools in older women with early breast cancer. Crit Rev Oncol Hematol 79:51–64.
    1. Owusu C, Koroukian SM, Schluchter M, Bakaki P, Berger NA (2011) Screening older cancer patients for a Comprehensive Geriatric Assessment: A comparison of three instruments. J Geriatr Oncol 2:121–129.
    1. Pottel L, Boterberg T, Pottel H, Goethals L, Van Den Noortgate N, et al. (2012) Determination of an adequate screening tool for identification of vulnerable elderly head and neck cancer patients treated with radio(chemo)therapy. J Ger Oncol 3:24–32.
    1. Pallis AG, Wedding U, Lacombe D, Soubeyran P, Wildiers H (2010) Questionnaires and instruments for a multidimensional assessment of the older cancer patient: What clinicians need to know? Eur J Cancer 46:1019–1025.
    1. Inouye SK, Peduzzi PN, Robison JT, Hughes JS, Horwitz RI, et al. (1998) Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 279:1187–1193.
    1. Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, et al. (2012) Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol 13:e437–e444.
    1. Falci C, Brunello A, Monfardini S (2010) Detecting functional impairment in older patients with cancer: is vulnerable elders survey-13 the right prescreening tool? An open question. J Clin Oncol 28:e665–e666.
    1. Luciani A, Floriani I, Foa P (2010) Reply to C. Falci et al. J Clin Oncol 28:e667.
    1. Barber JH, Wallis JB, McKeating E (1980) A postal screening questionnaire in preventive geriatric care. J R Coll Gen Pract 30:49–51.
    1. Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, et al. (2005) Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104:1998–2005.
    1. Overcash JA, Beckstead J, Moody L, Extermann M, Cobb S (2006) The abbreviated comprehensive geriatric assessment (aCGA) for use in the older cancer patient as a prescreen: scoring and interpretation. Crit Rev Oncol Hematol 59:205–210.
    1. Slaets JP (2006) Vulnerability in the elderly: frailty. Med Clin North Am 90:593–601.
    1. Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, et al. (2012) Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13:e148–e160.
    1. Saliba D, Elliott M, Rubenstein LZ, Solomon DH, Young RT, et al. (2001) The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 49:1691–1699.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever